A Retrospective Study of the Incidence of GIST in Scotland from 1995 to 1999Graham JS1*, Nowicki S1, Dunbar G1, Cowie F1, Dick C2, R Reid2, Walsh S3, White JD1 and Boyd K2
- *Corresponding Author:
- Graham JS
Consultant Medical Oncology
Beatson West of Scotland Cancer Centre
Great Western Road
E-mail: [email protected]
Received date: September 18, 2014; Accepted date: October 13, 2014; Published date: October 16, 2014
Citation: Graham JS, Nowicki S, Dunbar G, Cowie F, Dick C (2014) A Retrospective Study of the Incidence of GIST in Scotland from 1995 to 1999. J Clin Exp Pathol 4:196. doi:10.4172/2161-0681.1000196
Copyright: © 2014 Graham JS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background and aims: Gastrointestinal Stromal Tumours (GIST) are mesenchymal soft tissue neoplasms which express the c-kit receptor and are exquisitely sensitivity to tyrosine kinase receptor inhibitors such as imatinib. This has significantly improved prognosis so it is important to identify retrospective cases. Methods: Patients between 1995-1999 with suspected GIST were identified via Scottish pathology departments. C-kit + and C-kit -/CD34 + tumours were included. Data were analysed according to NIH consensus and the newer AFIP criteria. Results: The incidence of GIST was 0.69/100000/year. 44.8% were originally diagnosed as GISTs. Using NIH Consensus criteria there was a statistically significant relationship between overall survival and necrosis (p=0.004), prognostic group (p<0.0001) and mitotic rate (p=<0.0001). Overall survival was correlated with AIFP criteria (p value <0.0001). Conclusion: This pan Scotland study validates the AFIP criteria for assessment of overall survival in GISTs. In addition using the established NIH consensus criteria confirms a similar incidence to other European countries. We have identified patients who are eligible for targeted therapies who would otherwise have been missed.